Skip to main content
Clinical Trials/NCT05636241
NCT05636241
Completed
N/A

The Effect of Whole Body Vibration on Walking Parameters in Children With Cerebral Palsy

Kutahya Health Sciences University1 site in 1 country13 target enrollmentMay 20, 2023

Overview

Phase
N/A
Intervention
Not specified
Conditions
Cerebral Palsy
Sponsor
Kutahya Health Sciences University
Enrollment
13
Locations
1
Primary Endpoint
Spatiotemporal parameters of gait will be evaluated with the Zebris™ FDM-2 gait analysis platform.
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Some positive effects of whole body vibration applications in reducing spasticity, improving walking ability, and increasing walking speed have been reported in children with CP, but the evidence is not strong enough. Therefore, this study was planned to evaluate the effect of whole body vibration treatment on spasticity, gait, balance, and motor performance in children with spastic CP. This study hypothesis that whole body vibration provides an additive improvement on spasticity, balance, gait and motor performance.

Detailed Description

Participants will be evaluate at baseline, after the conventional physiotherapy program, and after whole body vibration training program. During this period, the participants who were recruited whole body vibration training program, whole body vibration will be applied in addition to conventional physiotherapy sessions comprised 45 min, 2 days a week, during 8 week.

Registry
clinicaltrials.gov
Start Date
May 20, 2023
End Date
August 31, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Kutahya Health Sciences University
Responsible Party
Principal Investigator
Principal Investigator

Eda Ozge OKUR

Assistant Professor

Kutahya Health Sciences University

Eligibility Criteria

Inclusion Criteria

  • Children diagnosed with spastic diplegic CP in GMFCS levels I and II, CFCS level I and MACS levels I and II
  • Aged 6-17 years
  • Ability to cooperate with the evaluations
  • Walking independently with or without an orthosis (without any support)

Exclusion Criteria

  • Having a recent injury affecting the lower extremities
  • Having undergone any surgery or Botulinuim Toxin application within the last six months
  • Having severe cardiopulmonary or systemic problems
  • Having uncontrolled seizures, visual or hearing problems preventing the evaluations

Outcomes

Primary Outcomes

Spatiotemporal parameters of gait will be evaluated with the Zebris™ FDM-2 gait analysis platform.

Time Frame: Change from baseline velocity at 2 months.

Gait analysis will be performed without any shoes and assistive devices. Walking evaluation on the gait platform will be limited to 1 minute. Obtained data about velocity will be collected as meters/seconds from the entire 1-minute walk will use for analysis.

Secondary Outcomes

  • The Pediatric Balance Scale will be used to measure functional balance of the participants.(Change from baseline score at 2 months.)

Study Sites (1)

Loading locations...

Similar Trials